NCT01021293View on ClinicalTrials.gov

Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

1,101

Participants

Timeline

Start Date

November 28, 2009

Primary Completion Date

July 5, 2010

Study Completion Date

July 5, 2010

Conditions
PoliomyelitisPoliomyelitis Vaccines
Interventions
BIOLOGICAL

Poliorix™

3 doses, intramuscular administration

BIOLOGICAL

Oral Poliovirus vaccine

3 doses, oral administration

Trial Locations (1)

Unknown

GSK Investigational Site, Wuzhou

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT01021293 - Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' Poliorix™ Vaccine | Biotech Hunter | Biotech Hunter